A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ontology highlight
ABSTRACT: This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).
DISEASE(S): Adenocarcinoma,Gynecologic Cancer,Lung Adenocarcinoma,Gastric Adenocarcinoma,Colorectal Cancer,Advanced Solid Tumor,Adenocarcinoma Of Lung,Head And Neck Cancer,Pancreatic Cancer,Breast Cancer
PROVIDER: 2361823 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA